Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1915 4
1948 1
1951 1
1953 2
1954 1
1955 2
1956 6
1957 3
1958 3
1961 10
1962 21
1963 34
1964 27
1965 36
1966 39
1967 65
1968 56
1969 48
1970 58
1971 70
1972 25
1973 27
1974 45
1975 43
1976 38
1977 66
1978 47
1979 57
1980 58
1981 74
1982 73
1983 69
1984 81
1985 114
1986 98
1987 110
1988 105
1989 108
1990 111
1991 94
1992 104
1993 119
1994 124
1995 125
1996 173
1997 155
1998 195
1999 225
2000 228
2001 237
2002 263
2003 247
2004 291
2005 327
2006 338
2007 311
2008 294
2009 308
2010 300
2011 366
2012 423
2013 426
2014 456
2015 467
2016 494
2017 485
2018 486
2019 521
2020 615
2021 707
2022 758
2023 92
Text availability
Article attribute
Article type
Publication date

Search Results

11,503 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y, Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T, Tachibana Y. Unoh Y, et al. Among authors: kato t. J Med Chem. 2022 May 12;65(9):6499-6512. doi: 10.1021/acs.jmedchem.2c00117. Epub 2022 Mar 30. J Med Chem. 2022. PMID: 35352927 Free PMC article.
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ, Naidoo J, Schumacher-Wulf E, Shitara K, Tsurutani J, Conte P, Kato T, Andre F, Powell CA. Swain SM, et al. Among authors: kato t. Cancer Treat Rev. 2022 May;106:102378. doi: 10.1016/j.ctrv.2022.102378. Epub 2022 Mar 12. Cancer Treat Rev. 2022. PMID: 35430509 Free article. Review.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: kato t. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: kato t. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Yoshino T, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Sakamoto Y, Shiozawa M, Nishi M, Horiuchi T, Yamagishi H, Sakamoto J, Mizushima T, Ohtsu A, Mori M. Yoshino T, et al. Among authors: kato t. J Clin Oncol. 2022 Oct 10;40(29):3419-3429. doi: 10.1200/JCO.21.02628. Epub 2022 May 5. J Clin Oncol. 2022. PMID: 35512259 Clinical Trial.
High-fat diet promotes prostate cancer growth through histamine signaling.
Matsushita M, Fujita K, Hatano K, Hayashi T, Kayama H, Motooka D, Hase H, Yamamoto A, Uemura T, Yamamichi G, Tomiyama E, Koh Y, Kato T, Kawashima A, Uemura M, Nojima S, Imamura R, Mubeen A, Netto GJ, Tsujikawa K, Nakamura S, Takeda K, Morii E, Nonomura N. Matsushita M, et al. Among authors: kato t. Int J Cancer. 2022 Aug 15;151(4):623-636. doi: 10.1002/ijc.34028. Epub 2022 Apr 26. Int J Cancer. 2022. PMID: 35403732
Versatile utilities of amphibians (part 2).
Michiue T, Zorn AM, Kato T, Ochi H, Hayashi T, Inoue T. Michiue T, et al. Among authors: kato t. Dev Growth Differ. 2022 Sep;64(7):346. doi: 10.1111/dgd.12810. Dev Growth Differ. 2022. PMID: 36173152 No abstract available.
Versatile utilities of amphibians (Part 3).
Michiue T, Kato T, Ochi H, Zorn A, Hayashi T, Inoue T, Kondo M, Taira M. Michiue T, et al. Among authors: kato t. Dev Growth Differ. 2022 Dec;64(9):472-473. doi: 10.1111/dgd.12829. Dev Growth Differ. 2022. PMID: 36579413 No abstract available.
Versatile Utilities of Amphibians (part 1).
Michiue T, Zorn AM, Kato T, Ochi H, Hayashi T, Inoue T. Michiue T, et al. Among authors: kato t. Dev Growth Differ. 2022 Aug;64(6):264-265. doi: 10.1111/dgd.12805. Dev Growth Differ. 2022. PMID: 36088539 No abstract available.
11,503 results
You have reached the last available page of results. Please see the User Guide for more information.